Truist Financial Reiterates “Buy” Rating for Encompass Health (NYSE:EHC)

Truist Financial reaffirmed their buy rating on shares of Encompass Health (NYSE:EHC) in a research report released on Monday,Benzinga reports. They currently have a $135.00 target price on the stock, up from their previous target price of $116.00.

Other equities research analysts have also recently issued research reports about the company. Barclays lifted their price target on Encompass Health from $118.00 to $129.00 and gave the company an “overweight” rating in a report on Friday, April 25th. StockNews.com upgraded Encompass Health from a “hold” rating to a “buy” rating in a research report on Friday, April 25th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $110.00 price objective on shares of Encompass Health in a report on Tuesday, February 11th. KeyCorp raised their price objective on shares of Encompass Health from $120.00 to $122.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Finally, William Blair reissued an “outperform” rating on shares of Encompass Health in a research note on Friday, February 7th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $120.86.

Encompass Health Trading Up 1.1 %

Encompass Health stock opened at $117.14 on Monday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05. Encompass Health has a 1 year low of $82.38 and a 1 year high of $117.52. The firm’s 50-day moving average is $101.07 and its 200-day moving average is $98.96. The company has a market cap of $11.80 billion, a P/E ratio of 26.26, a PEG ratio of 2.31 and a beta of 0.87.

Encompass Health (NYSE:EHC) last issued its earnings results on Thursday, April 24th. The company reported $1.37 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.18. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. Encompass Health’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.12 earnings per share. On average, equities analysts expect that Encompass Health will post 4.8 earnings per share for the current year.

Encompass Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Tuesday, April 1st were given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date of this dividend was Tuesday, April 1st. Encompass Health’s dividend payout ratio (DPR) is presently 14.05%.

Insiders Place Their Bets

In other news, EVP John Patrick Darby sold 10,000 shares of Encompass Health stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the transaction, the executive vice president now owns 79,710 shares in the company, valued at approximately $9,149,910.90. The trade was a 11.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Andrew L. Price sold 5,042 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the sale, the chief accounting officer now directly owns 69,164 shares of the company’s stock, valued at approximately $6,798,129.56. This represents a 6.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Encompass Health

Several institutional investors and hedge funds have recently modified their holdings of the stock. State of Michigan Retirement System raised its stake in shares of Encompass Health by 1.3% during the 1st quarter. State of Michigan Retirement System now owns 24,145 shares of the company’s stock worth $2,445,000 after purchasing an additional 300 shares in the last quarter. Alps Advisors Inc. lifted its stake in shares of Encompass Health by 9.8% in the 1st quarter. Alps Advisors Inc. now owns 200,462 shares of the company’s stock valued at $20,303,000 after purchasing an additional 17,832 shares during the last quarter. TD Private Client Wealth LLC lifted its position in shares of Encompass Health by 23.3% in the first quarter. TD Private Client Wealth LLC now owns 3,065 shares of the company’s stock worth $310,000 after buying an additional 580 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Encompass Health by 6.8% during the 1st quarter. Envestnet Asset Management Inc. now owns 296,861 shares of the company’s stock worth $30,066,000 after acquiring an additional 18,885 shares in the last quarter. Finally, Braun Stacey Associates Inc. increased its holdings in shares of Encompass Health by 17.4% during the 1st quarter. Braun Stacey Associates Inc. now owns 123,205 shares of the company’s stock valued at $12,478,000 after acquiring an additional 18,298 shares during the last quarter. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.